Alpha 2.0
Login Register
» Authors » I Vergote

I Vergote

Explore the profile of I Vergote including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 260
Citations 5744
Followers 0
Related Specialties
Oncology
Gynecology & Obstetrics
General Medicine
Top 10 Co-Authors
F Amant
P Neven
D Timmerman
P Berteloot
K Leunen
P Moerman
B Van Calster
H Wildiers
A du Bois
J Sehouli
Published In
Ann Oncol
Gynecol Oncol
Int J Gynecol Cancer
Eur J Cancer
Ultrasound Obstet Gynecol
Affiliations
Soon will be listed here.
Recent Articles
11.
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion
Vergote I, Denys H, Altintas S, Kerger J, Baurain J, Bours V, et al.
Facts Views Vis Obgyn . 2022 Jul; 14(2):111-120. PMID: 35781107
Ovarian cancer (OC) has a poor prognosis as most patients present with non-specific symptoms and the disease is mostly diagnosed at advanced stages. Approximately 90% of cases are classified as...
12.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Francis K, Kim S, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, et al.
Ann Oncol . 2022 Feb; 33(6):593-601. PMID: 35219776
Background: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA-mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy. In the SOLO2...
13.
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Vergote I, Gonzalez-Martin A, Ray-Coquard I, Harter P, Colombo N, Pujol P, et al.
Ann Oncol . 2021 Dec; 33(3):276-287. PMID: 34861371
Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR...
14.
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours
Timmerman D, Planchamp F, Bourne T, Landolfo C, Bois A, Chiva L, et al.
Facts Views Vis Obgyn . 2021 Jun; 13(2):107-130. PMID: 34107646
The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological...
15.
Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses
Verschuere H, Froyman W, Van den Bosch T, Van Hoefs M, Kaijser J, Van Schoubroeck D, et al.
Gynecol Oncol . 2021 Apr; 161(3):845-851. PMID: 33858675
Objective: To assess the safety, adequacy and accuracy of transvaginal ultrasound-guided tru-cut biopsy of pelvic masses. Methods: We performed a retrospective analysis of consecutive women who underwent transvaginal ultrasound-guided tru-cut...
16.
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors
Timmerman D, Planchamp F, Bourne T, Landolfo C, Bois A, Chiva L, et al.
Ultrasound Obstet Gynecol . 2021 Apr; 58(1):148-168. PMID: 33794043
The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological...
17.
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Moore K, Oza A, Colombo N, Oaknin A, Scambia G, Lorusso D, et al.
Ann Oncol . 2021 Mar; 32(6):757-765. PMID: 33667670
Background: Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The randomized, open-label, phase III...
18.
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort
Thijssen S, Wildiers H, Punie K, Beuselinck B, Clement P, Remmerie C, et al.
J Cancer Res Clin Oncol . 2021 Jan; 147(4):1041-1048. PMID: 33471187
Purpose: In metastatic breast cancer (MBC) population treated with capecitabine monotherapy, we investigated clinical-pathological features as possible biomarkers for the oncological outcome. Methods: Retrospective study of consecutive MBC patients treated...
19.
Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease
Vandewal A, Delbecque K, Van Rompuy A, Noel J, Marbaix E, Delvenne P, et al.
Eur J Obstet Gynecol Reprod Biol . 2020 Dec; 257:95-99. PMID: 33383413
Objective: We assessed the curative effect of a second curettage in patients with persistent hCG serum levels after first curettage for a gestational trophoblastic disease (GTD). Study Design: This prospective...
20.
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study
Cibula D, Dostalek L, Hillemanns P, Scambia G, Jarkovsky J, Persson J, et al.
Eur J Cancer . 2020 Dec; 143:88-100. PMID: 33290995
Background: The management of cervical cancer patients with intraoperative detection of lymph node involvement remains controversial. Since all these patients are referred for (chemo)radiation after the surgery, the key decision...